Rolontis

Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Rolontis (eflapegrastim) HENDERSON, Nev.–(BUSINESS WIRE)–Aug. 6, 2021– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s…